ArticleBMC cancer2022

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.

Tetsuhiko Asao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.